IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Immunome Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Aug 11, 2026
$16.77+0.30 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $1.90B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.10 (+7.02%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Immunome Inc. saw revenue fall 63.3% to $4.02M over the twelve months to Mar 31, 2026. Free cash flow was -$205.52M.
Revenue
$4.02M
-63.3% vs. a year earlier
Operating income
-$238.81M
TTM Q1 2026
Free cash flow
-$205.52M
TTM Q1 2026
EPS, diluted
-$2.37
TTM Q1 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Mar 31, 2026
Valuation
- Market cap
- $1.90B
- P/E ratio
- –
- Price to sales
- 472.55
- Price to book
- 3.22
- Dividend yield
- –
- Free cash flow yield
- -10.83%
Fundamentals
- Revenue
- $4.02M
- Net income
- -$224.59M
- EPS, diluted
- -$2.37
- Free cash flow
- -$205.52M
- Book value per share
- $5.20
- Diluted shares
- 113M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$4.02M-63.3% YoY
Operating income
-$238.81M
Net income
-$224.59M
EPS, diluted
-$2.37
Free cash flow
-$205.52M
Reported periodTrailing twelve months